Cargando…
Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
There is overwhelming evidence that optimal adjuvant endocrine therapy for hormone sensitive breast cancer in postmenopausal women should include a third generation aromatase inhibitor (AI). On current evidence, adjuvant anstrozole or letrozole should be used upfront in such patients especially in t...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1586206/ https://www.ncbi.nlm.nih.gov/pubmed/16981992 http://dx.doi.org/10.1186/1477-7800-3-31 |